Introduction
The Bernard-Soulier syndrome ( 1, 2) is a congenital bleeding disorder characterized by giant platelets with an absent or dysfunctional platelet membrane receptor, the glycoprotein (GP)' Ib-IX-V complex (3) . At sites of vascular injury, the GP Iba component ofthis receptor interacts with the adhesive protein, von Willebrand factor (vWF), to support platelet adhesion and initiate thrombus formation (3) . The GP Ib-IX-V receptor is assembled from four distinct gene products into a hetero-oligo- 1 . Abbreviations used in this paper: CHO, Chinese hamster ovary; GP, platelet membrane glycoprotein; PCR, polymerase chain reaction. meric complex composed of the disulfide-linked a-(4, 5) and f3-subunits (6) of GP lb associated in a noncovalent manner with GP IX (7) and GP V (8, 9) . Most cases ofBernard-Soulier syndrome may be caused by a genetic defect within one of the subunits, preventing a coordinated assembly of the complex and, thus, membrane expression (10) . The validity ofthis concept has been proven in a family bearing a nonsense mutation in the GP Iba gene (11 ) and by the coordinated expression ofa recombinant GP Ib-IX complex on the surface ofheterologous cells ( 12) .
In contrast to the classical form of the disease, a previously characterized variant ofBernard-Soulier syndrome, designated type Bolzano, was found to express a dysfunctional GP Ib-IX-V complex on the surface of giant platelets that lacked the ability to bind vWF ( 13) . In this report we demonstrate that the latter abnormality is caused by an Ala'56 -. Val substitution within the conserved leucine-rich motif present in GP Iba ( 14) . Expression of an isolated recombinant GP Iba analogue containing the mutation resulted in a structural and functional abnormality equivalent to that associated with type Bolzano platelets. These findings establish that the leucine-rich motif is an important structural element in the GP Ib-IX-V complex and is required for normal platelet activity in hemostasis.
Methods
Bernard-Soulier syndrome, type Bolzano. The propositus was previously described as a typical case of Bernard-Soulier syndrome, with giant platelets exhibiting a markedly decreased vWF-binding capacity ( 1 3, 15) . Detailed immunochemical studies revealed also a major structural abnormality ofGP Iba characterized by the absence ofconformation-dependent epitopes recognized by specific monoclonal antibodies ( 13) .
Genetic studies. Blood samples were obtained from the propositus, other family members, and normal blood donors recruited through the General Clinical Research Center of Scripps Clinic. All individuals were informed of the purpose of these studies and gave their consent according to the Declaration of Helsinki. Genomic DNA was isolated from peripheral lymphocytes using standard procedures ( 16) . Bacteriophage clones containing the propositus' GP Iba gene were isolated from a library ofEcoRI restriction fragments propagated in the cloning vector XZAP (Stratagene Cloning Systems, La Jolla, CA) ( 17) . Purified bacteriophages were characterized by restriction enzyme mapping, and this analysis identified an EcoRI fragment of 6,000 bp in length containing the entire GP Iba gene; this fragment was subsequently subcloned into pBS/SK-for DNA sequence analysis. The coding sequence for the propositus' GP Iba was also amplified by polymerase chain reactions (PCR) ( 18) into a series of overlapping fragments that generated a composite array of the GP Iba gene. PCR fragments were subcloned into the Ml 3 vector before DNA sequence analysis. The latter was performed using GP Iba-specific oligonucleotides synthesized according to published GP Iba sequences (5, 19) . Southern transfer and hybridization were performed essentially as described ( 17) .
Two missense mutations corresponding to residues 145 and 156 of GP Iba were identified during the course of these studies. A 591-bp fragment containing the coding sequence for GP Iba residues 106-302 (residue numbers are referenced from His' of mature GP Iba) was generated by PCR and used for the characterization of the two mutations. The oligonucleotide primers used in the PCR contained nucleotides 899-919 and 1470-1489, as numbered in the published sequence (19) .
Monoclonal andpolyclonal antibodies. The production and characterization ofthe anti-GP Iba monoclonal antibodies used in these studies have been described elsewhere (20) (21) (22) . Antibody LJ-Ibal recognizes an epitope located within residues 1-237 and reacts with SDSdenatured and reduced GP Iba antigen. Antibodies LJ-Ibl, LJ-P3, and LJ-PI9 react with epitopes that are destroyed by treatment with SDS and are located in an amino-terminal 45-kD tryptic fragment of GP Iba composed of residues 1-293. A rabbit polyclonal antibody was generated using a synthetic peptide composed of GP Iba residues Gly27'-Glu285.
Expression ofrecombinant GPIbafragments. The characterization of a recombinant plasmid synthesizing a functional amino-terminal domain of GP Iba has been described in detail elsewhere (22) . Briefly, a mammalian cell expression plasmid was constructed from a fragment of the GP Iba gene (coding for signal peptide and mature residues His'-Ala302) synthesized in a PCR that added BamHI restriction sites on the ends ofthe amplified fragment. The amplified GP Iba fragment was cloned into MI3mpl9 as a BamHI fragment and sequenced to verify that no spontaneous mutations had arisen during the PCR. The GP Iba insert was removed from the M 13 construct by digestion with EcoRI and XbaI and cloned into the same restriction sites of the polylinker region of PBS/KS-(Stratagene). As a result of cloning into PBS/KS-, restriction sites for XhoI (5' to the GP Iba initiating Met codon) and NotI (3' to the Ala'2 codon) were acquired from the polylinker region and were used to clone the fragment into the mammalian cell expression plasmid, pCDM8nW. The latter is identical to pCDM8 (23) except that it contains a neomycin gene for conferring resistance to the aminoglycoside antibiotic, G418 or Geneticin (Sigma Chemical Co., St. Louis, MO).
Mutations within the expression plasmid were constructed using mutagenic oligonucleotides and site-directed mutagenesis on uracilcontaining templates of the original M13 construct (24) . After mutagenesis and subcloning into PBS/KS-(described above), the mutant GP Iba coding regions were completely sequenced to ensure that no additional mutagenic errors had occurred and then were cloned into the pCDM8" expression plasmid.
Chinese hamster ovary (CHO-KI) cells were maintained in 5% CO2 and grown in DME supplemented with 10% fetal calfserum (10%-DME), 0.5 mM nonessential amino acids, and 2 mM L-glutamine ( (24 h ) and harvested for immunoblotting. The dot-blot technique used to evaluate the immunochemical reactivity ofrecombinant fragments has been described in detail elsewhere (22) . In brief, proteins in the culture medium were immobilized onto nitrocellulose membranes by filtration, reacted with the appropriate specific antibody, and detected by autoradiography after incubation with '251-labeled rabbit anti-mouse IgG or 1251-labeled goat anti-rabbit IgG (22) . vWF binding to immobilized recombinantfragments. The method used for this assay has been described in detail elsewhere (22) . All reagents were filtered (in -5 min for each step) through a nitrocellulose membrane (0.45-Mm pore size; Bio-Rad Laboratories, Hercules, CA) using a peristaltic pump applied to a device that delimits a circular area of application (22) . All the steps of this assay were performed at room temperature (22-250C) . Serum-free culture media from different cell lines were either diluted with the appropriate amount ofserumfree medium from nontransfected CHO-KI cells or used in volumes (30- (22), was filtered through the nitrocellulose membrane. The specific activity of the different preparations of 1251-vWF used varied between 13 and 140 ,Ci/mg. Ristocetin (Sigma Chemical Co.) was used at the final concentration of 1 mg/ml; botrocetin (two-chain form) was purified as previously described in detail (26, 27) from the crude venom of Bothrops jararaca (Sigma Chemical Co.) and was used at the final concentration of 10 ,g/ml. When indicated, appropriate anti-GP Iba monoclonal antibodies (the combination of LJ-Ibl and LJ-P19, 100 Mg/ml each) were added to these mixtures before filtering through the nitrocellulose; a solution of the same antibodies was also filtered through the membrane before application ofthe vWF-containing mixture. After two additional washes in the blocking solution, the membrane was dried, the portion of the membrane corresponding to each application well was cut out, and the bound radioactivity determined in a y-scintillation spectrometer. In the assays using the modulator ristocetin, the latter was also present in the final washing fluid at the same concentration used during the incubation with vWF. It is important to note that the addition ofbovine y-globulin to the solution used to block the nitrocellulose membrane proved essential to reduce the level ofnonspecific binding, particularly when ristocetin was utilized as modulator. Binding was considered nonspecific when it occurred in the absence of recombinant GP Iba fragment and/or was not inhibited by appropriate anti-GP Iba monoclonal antibodies. Indeed, in several experiments performed without the use of y-globulin in the blocking solution, we found variable nonspecific vWF binding to one or more component present also in nontransfected CHO-Kl cell culture media.
In total, of nine different control media tested for apparent vWF binding in the presence of ristocetin, only three exhibited values corresponding to background; four exhibited apparent binding that was 2 50%, and two > 100% ofthat measured with the medium containing normal GP Iba fragment. The same variable level of vWF binding was observed with fragments containing the Ala' -* Val mutation; in either case, however, this nonspecific binding was essentially abolished when the nitrocellulose membrane was blocked with the solution containing bovine y-globulin (see Results). Use of the latter, therefore, represents a crucial modification ofthe method previously described to measure vWF binding to recombinant GP Iba fragments (22 Met mutation was subsequently determined to be a genetic dimorphism found in the normal population with an allele frequency of 11% (n = 122) (28, 29); the Ala'56 --Val mutation, in contrast, was not detected in DNA fragments generated from normal individuals. 1489
The propositus was also homozygous, and both his parents were heterozygous, for a triplication of39 nucleotides encoding residues 399-411 (Fig. 2) . This is another GP Iba polymorphism, described also by others (30) , that in our studies was found to occur with an allele frequency of 13% (n = 24). 156 Immunologic consequences ofthe a-subunit missense mutations. We have previously shown that the amino-terminal domain ofGP Iba is structurally and functionally mimickedby a 302-residue recombinant fragment that can be independently expressed and secreted as a soluble species from CHO-Kl cells (22 (22) . The epitope of one of these antibodies, designated LJ-Ib 1, was previously found to be typically absent in platelets from the type Bolzano propositus ( 13 ). Therefore, to evaluate the immunological consequences of the identified mutations, we expressed fragments bearing the dimorphism (Thr'45 -. Met) and the unique point mutation identified in the Bernard-Soulier variant (Ala'56 _O Val) either independently or in association (the latter representing the genotype of the propositus) and compared their immunoreactivity to that of the GP Iba fragment with normal sequence. Like platelets from the propositus (13), the GP Iba fragment bearing the Thr'45 _I Met and Ala'56 _. Val mutations had markedly decreased reactivity with LJ-Ib and other conformation-dependent anti-GP Ib monoclonal antibodies (Fig. 3) . The fragment bearing the single Ala'56 -* Val mutation also demonstrated a similar abnormal reactivity, but a fragment with the single Thr 145 -Met mutation reacted normally (Fig. 3) . This demonstrates that the Ala'56 -) Val mutation is responsible for the alteration in antibody recognition associated with the propositus' abnormal GP Ib-IX-V complex on platelets, regardless of the dimorphic residue at position 145. All mutant fragments reacted equally well with the conformation-independent antibody, LJ-Ibal, after reduction of intramolecular disulfide bonds (Fig. 3) ; the latter, then, could be used to demonstrate the presence ofimmunoreactive GP Iba-related protein in different culture media.
Functional consequences of the a-subunit missense mutations. In a previous publication we have proposed the concept that the vWF-binding function of the platelet GP Ib-IX-V complex can be recapitulated in the soluble recombinant GP Iba fragment containing residues 1-302 (22) . We based our conclusions on the following observations: (a) the binding of soluble vWF to immobilized recombinant fragment as well as to the intact GP Ib-IX-V receptor complex on platelets requires the presence ofa modulator, either ristocetin or botrocetin; (b) the binding ofpurified vWF to immobilized recombinant fragment can be inhibited with the same monoclonal antibodies that inhibit binding to the GP Tb-IX-V complex; and (c) vWF binding to immobilized recombinant fragment and intact GP lb-IX-V complex on platelets exhibits essentially the same apparent affinity (22) . In agreement with this concept, expression of the mutation identified in the type Bolzano BernardSoulier variant resulted in a dysfunctional recombinant fragment lacking vWF-binding activity, similar to the abnormality observed with intact platelets from the propositus ( 13). Indeed, using either ristocetin or botrocetin as modulators of vWF binding, it was apparent that the GP Iba fragment bearing Additional binding experiments performed with increasing ligand concentrations confirmed that the mutant fragment expressing the type Bolzano phenotype fails to interact with vWF both in the presence of ristocetin (Fig. 5) and botrocetin (Fig.   6 ). Moreover, a GP Iba fragment containing the Ala 156 -Val mutation but the more common threonine at position 145 exhibited the same loss of activity as the fragment containing Met'45 (Figs. 5 and 6) , confirming that the effects ofthe mutation at position 156 are not influenced by the dimorphism at position 145. In this regard, therefore, vWF-binding studies and immunochemical studies (Fig. 3) gave concordant results. It should be noted that, under the experimental conditions used, the interaction of vWF with recombinant GP Iba fragments is not reversible; thus, since binding is not at equilibrium, we chose not to submit the data to Scatchard-type analysis. The results obtained in this study with the normal GP Iba fragment, however, are similar to those reported previously and calculated to give apparent dissociation constant comparable to that measured for vWF binding to intact GP Ib-IX complex on platelets (22) .
Discussion
The pathogenesis of the Bernard-Soulier syndrome may parallel, in most instances, congenital abnormalities of other multisubunit receptor complexes, such as integrins (31, 32) , to the extent that a defect in a single subunit prevents assembly and surface expression of the entire complex (1 1, 12) . Among the reported cases of Bernard-Soulier syndrome, however, type Bolzano represents a unique example since the GP lb-IX-V complex is present on the platelet surface, albeit with a reduced number of copies, but is dysfunctional, showing normal ability to bind a-thrombin but defective vWF binding function ( 13 ) . In previous studies ( 13), we suggested that the genetic defect resulting in the type Bolzano phenotype was likely to be localized in the a-subunit of GP lb for two reasons: (a) vWF binding to the receptor, the function defective in platelets from the propositus, is an intrinsic property of the amino terminus of GP Iba (21, 22) ; and (b) immunological characterization of the propositus' platelets demonstrated loss ofthe epitope recognized by the monoclonal antibody LJ-Ib 1, located within residues 1-293 of the GP Iba-chain (20) . Indeed, we have now found that the propositus' GP Iba gene contains a unique Ala 156 -. Val substitution as well as two polymorphic markers, a Met 145 codon instead ofthe more common Thr'45 and coding sequence for 26 additional residues within the carbohydraterich domain. In the previous characterization of the propositus' family (13) , the binding of antibody LJ-Ibl to the mother's platelets was reported to be 50% of normal, a finding consistent with the possibility of genetic heterozygosity. Indeed, it is now apparent that both parents ofthe propositus are obligatory carriers for the Bernard-Soulier syndrome, since they have both a mutant (Val 156) and a normal (Ala 156) GP Iba allele. The presence of the same two polymorphic markers in the alleles containing the Val '56 codon in both parents suggests that the type Bolzano phenotype is the consequence of a consanguineous mating.
Immunological characterization of recombinant fragments corresponding to the 45-kD amino-terminal domain ofGP Iba established a direct correlation between presence of the Val 156 mutation and loss ofthe epitope recognized by the monoclonal antibody LJ-Ibl, the same defect exhibited by platelets from 1L X L X X N X L8 X X L P X G L15 X X X L X X L22 X X24 Leucine-rich consensus Figure 7 . Sequence alignment (sin- platelet GP Iba. Leucine-rich repeats form the basis for a family of proteins containing a 24-residue motif with leucine residues at every seventh position and other conserved hydrophobic and hydrophilic residues interspersed among them ( 14) . The variant residues ofthe leucine-rich consensus sequence are designated by X. The molecular defect resulting in the Bolzano variant of the Bernard-Soulier syndrome is an Ala'56 -. Val substitution and is shown at its corresponding position within a leucine-rich repeat. Sequence alignment of 138 leucine-rich repeats from 16 different proteins in the Protein Information Resource database revealed that the fourth position of the repeat, which corresponds to the identified mutation within platelet GP Iba, is occupied by noncharged amino acids in 65% of the repeats. 71% of the noncharged residues are Ser or Gly. None of the 138 complete leucine-rich repeats examined exhibited the hydrophobic residues Val, Leu, Ile, and Pro at the fourth position of the consensus sequence, whereas every other amino acid was represented at that position in at least one repeat.
the type Bolzano propositus ( 13) . This amino acid substitution is not likely to affect selectively the antibody contact site but, rather, appears to have a more complex effect on the conformation of the expressed molecule. In fact, two other anti-GP Iba monoclonal antibodies, each recognizing distinct epitopes sensitive to denaturation (20, 22) , showed decreased interaction with recombinant fragments containing the Val1'6 mutation. Similar results have also been observed with platelets from the type Bolzano propositus, supporting the conclusion that the effects ofthe Ala'56 -_ Val mutation are essentially the same in the isolated GP Iba amino-terminal fragment as they are in the GP lb-IX-V complex on intact platelets. It is also clearly indicated by our experimental findings that the mutation at residue 156 by itself explains the abnormal immunochemical reactivity ofthe type Bolzano GP Iba molecule, without relevant contribution by the dimorphism at position 145. It should be remembered, however, that the Thr/Met dimorphism, per se, can independently create a new antigenic site on GP Iba as well as on the expressed recombinant fragment (29) .
The results of studies on the functional properties of the expressed mutant GP Iba fragments support the concept that the Ala'56 _. Val mutation, in addition to causing a structural abnormality resulting in the loss ofconformation-sensitive epitopes, is also responsible for decreased vWF binding. Two exogenous modulators were used in these assays, ristocetin and botrocetin, as commonly done to measure the binding of native soluble vWF to platelets. These modulators may mimic events that occur at a site of vascular injury where soluble vWF becomes adsorbed onto exposed subendothelial structures and then promotes the attachment of platelets through the GP Ib-IX-V complex (33) . Botrocetin forms a bimolecular complex with vWF that, in turn, binds specifically to GP Iba (27) ; ristocetin acts in a less well-defined manner, but is thought to require interaction with both vWF and the platelet membrane in order to promote vWF binding to GP Iba (34) . It ( 14) . All four subunits of the GP Ib-IX-V complex contain this motif characterized by a conserved spacing of leucine residues within a 24-amino acid sequence (4) (5) (6) (7) (8) . There are similarities and dissimilarities between the leucine-rich repeats and the well-characterized leucine-zipper motif ( 14) . The most striking similarity is the predominance of leucine residues and their similar spacing at every seventh position (Fig. 7) ; however, the leucine-rich repeats have a high content of proline residues that are likely to interfere with the formation of the regular coiled-coil structure that serves as the backbone for the leucine-zipper (38) . The three-dimensional conformation of leucine-rich repeats is unknown, but it has been proposed that they form amphipathic , sheets (39) . Perhaps, the local increase in hydrophobicity caused by the Ala'56 Val mutation may alter the amphipathic structure and interfere with the surface orientation of residues involved in interactions that are essential for the structural and functional integrity of GP Iba. It is noteworthy that in > 100 homologous sequences present in the protein database, the position corresponding to residue 156 in GP Iba is predominantly occupied by polar residues; thus far, valine, leucine, isoleucine, and proline have never been found in that position (Fig. 7) . It has been proposed that leucine-rich repeats may be involved in protein-membrane and protein-protein interactions (37, (39) (40) (41) isolated soluble fragment of GP Iba. Thus, such function does not require interactions with the platelet membrane; moreover, it is clearly intrinsic to the a-chain and independent of association with homologous sequences in the other components of the receptor complex.
Previous results obtained with synthetic peptides (42) and recombinant fragments (22) indicate that a domain relevant for vWF-binding function is located between residues 221 and 318 of GP Iba, with a predominant role for a cluster of negatively charged residues between positions 25 1 and 279 (Fig. 1) . The leucine-rich repeats may provide the conformation necessary for the function ofthis site, e.g., affecting the orientation of charged residues, without necessarily having a direct participation in establishing contact with the ligand. Such structural effects may be achieved through self-interactions ofthe homologous leucine-rich sequences, a function that may be regulated through the number of repeats present in a given molecule. That the Ala'56 -Val substitution may indeed alter the conformation of the amino terminal domain of GP Iba is suggested by the evidence that the type Bolzano mutant has not only an abnormal interaction with vWF but also markedly decreased reactivity with three different monoclonal antibodies each recognizing distinct and nonoverlapping epitopes (20, 22, 42) . Appropriate conformation maintained by the leucine-rich repeat region in the extracytoplasmic domain may also influence the linkage of the intracytoplasmic tail of GP Iba to the cytoskeleton (43) , so that the Ala'56 --Val mutation may be responsible for both the ligand binding defect and the aberrant morphology of giant platelets in the type Bolzano variant.
